Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx, Inc. (NASDAQ: CVRX) has received FDA approval for MR conditional labeling of its Barostim System, allowing heart failure patients with the device to safely undergo MRI scans of the head and lower extremities. This approval enhances diagnostic options for patients receiving Barostim therapy. Barostim, the first FDA-approved neuromodulation device for heart failure, helps improve symptoms by stimulating baroreceptors. In clinical studies, patients demonstrated improved walking distance, quality of life, and reduced cardiovascular events compared to a control group.
CVRx reported a 43% increase in first quarter 2022 revenue, totaling $4.1 million, driven by strong U.S. heart failure revenue growth of 133% to $2.9 million. The company achieved notable milestones, including an expansion of active implanting centers from 19 to 56 and territories from 6 to 17 year-over-year. Despite these gains, net loss widened to $10 million or $0.49 per share, and European revenue fell 18%. The outlook for 2022 remains positive, projecting total revenue between $20 million and $23 million.
CVRx announced plans to release its first quarter 2022 financial results on April 25, 2022, after market close. The company will host a conference call at 4:30 p.m. ET the same day for discussion of the results. Investors can join the call by dialing (833) 730-3980 for U.S. participants or +1 (720) 405-2140 for international callers, using the conference code 8433167. CVRx specializes in neuromodulation solutions for cardiovascular diseases, including the FDA-approved Barostim device, aimed at improving heart failure symptoms.
CVRx reported a significant 75% revenue increase for Q4 2021, reaching $3.7 million compared to Q4 2020. Key growth drivers included U.S. heart failure revenue, which soared 345% year-over-year to $2.7 million. For the full year, CVRx achieved a 115% total revenue increase to $13 million and fully repaid a $20 million loan in November 2021. The company anticipates total revenue between $20 million and $23 million for 2022, with an improved gross margin forecast of 74% to 76%.
CVRx, a commercial-stage medical device company, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. The company will hold a conference call at 5:30 p.m. Eastern Time to discuss the results. Investors can join by dialling (833) 730-3980 for U.S. callers or +1 (720) 405-2140 internationally, referencing conference code 2879175. The FDA-approved Barostim™ device is designed to improve heart failure symptoms by stimulating the body's baroreceptors.
CVRx reported preliminary fourth quarter 2021 revenues of approximately $3.6 million to $3.7 million, a 71% to 77% increase from Q4 2020. Full year 2021 revenue is projected at $13.0 million to $13.1 million, reflecting a 113% to 116% growth from 2020. The company had 46 active implanting centers and reported cash and equivalents of $142 million. For 2022, CVRx anticipates total revenue between $20 million and $23 million with operating expenses of $55 million to $61 million. Despite challenges in Europe, the U.S. heart failure sector shows resilience.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 pm ET. The presentation will be available via a live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. CVRx is known for its FDA-approved Barostim device that alleviates symptoms of heart failure through electrical pulses to baroreceptors, receiving both FDA Breakthrough Device designation and CE Mark approval.
CVRx, a medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The management team's pre-recorded fireside chat is scheduled for November 22, 2021, at 10:00 a.m. ET, accessible via their investor relations page at ir.cvrx.com.
CVRx is known for Barostim™, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms, receiving both the FDA Breakthrough Device designation and CE Mark for its effectiveness.
CVRx reported Q3 2021 revenue of $3.4 million, a notable 241% increase year-over-year. U.S. heart failure revenue surged to $2.5 million from $0.1 million in the prior year. The company successfully closed its IPO in July 2021, raising net proceeds of approximately $133.2 million, and has since fully repaid a $20 million loan. The outlook for 2021 remains positive, with projected revenue between $13.3 million and $13.9 million. Additionally, CVRx filed three PMA Supplement applications with the FDA to enhance its Barostim platform.
CVRx, a medical device company, will release its third quarter financial results on November 4, 2021, after market close. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time the same day. U.S. callers can dial (833) 730-3980, while international callers should use +1 (720) 405-2140, referencing conference code 6038756. CVRx is known for developing Barostim™, an FDA-approved neuromodulation device that helps heart failure patients by restoring balance to the autonomic nervous system.